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Abstract: We report the case of a patient with an aggressive retinal astrocytoma accompanied with 
macular edema and neovascular vessels, who was initially treated with intravitreal bevacizumab 
injections. A 24-year-old male presented to our clinic complaining of visual disturbance in his 
right eye. At 8 years of age, he had been diagnosed as having tuberous sclerosis complex. Fundus 
examination demonstrated a retinal tumor accompanied with marked neovascular vessels on the 
surface, retinal hemorrhage, and macular edema. After six monthly intravitreal bevacizumab injec-
tions, fundus examination demonstrated marked regression of the macular edema and neovascular 
vessels. Two months later, a vitreous hemorrhage developed which necessitated pars plana vitrec-
tomy. After additional intravitreal bevacizumab injection for preventing intraoperative bleeding, 
vitrectomy with endophotocoagulation for the tumor was performed. The vitreous sample was 
obtained during vitrectomy, and we measured the vascular endothelial growth factor concentration 
by enzyme-linked immunosorbent assay. The surgically removed epiretinal neovascular membrane 
and biopsied retinal tumor expressed vascular endothelial growth factor, although several intravit-
real bevacizumab injections led to a vitreous vascular endothelial growth factor concentration of 
undetectable levels. The clinical course and immunohistochemical analyses indicate that intravitreal 
bevacizumab monotherapy may have been insufficient to treat the aggressive retinal astrocytoma 
with macular edema and that laser photocoagulation or photodynamic therapy for the tumor should 
be considered following intravitreal bevacizumab injection in such cases.
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Introduction
Retinal astrocytoma associated with tuberous sclerosis complex is a relatively static 
lesion with little potential for aggressive behavior. Aggressive retinal astrocytoma 
associated with tuberous sclerosis complex is a rare variant of this usually benign 
astrocytoma, and the tumor enlarges progressively, leading to complications, including 
exudative retinal detachment, vitreous hemorrhage, and neovascular glaucoma.1,2 It has 
been reported that aggressive retinal astrocytoma can be treated with laser photoco-
agulation, photodynamic therapy, or intravitreal bevacizumab injection.2–7 Herein, we 
report the case of a patient with aggressive retinal astrocytoma and macular edema 
who was initially treated with intravitreal bevacizumab injection. However, after six 
monthly intravitreal bevacizumab injections, vitreous hemorrhage developed which 
necessitated vitrectomy with endophotocoagulation. The surgically removed epiretinal 
membrane and biopsied retinal tumor expressed vascular endothelial growth factor 
(VEGF) despite preceding intravitreal bevacizumab injection.
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Case report
A 24-year-old male presented to our clinic complaining of 
visual disturbance in his right eye. At 8 years of age, he had 
been diagnosed as having tuberous sclerosis complex. He had 
mental retardation, a medical history of epilepsy, and obvious 
facial angiofibromas. Genetic testing was not performed. The 
best-corrected visual acuity (BCVA) was 0.09 in the right eye 
and 1.2 in the left eye. Anterior segments and ocular media 
were unremarkable in both eyes. The fundus was normal in 
the left eye. In the right eye, fundus examination demon-
strated an elevated lesion in the superior aspect of the optic 
disc accompanied with marked neovascular vessels on the 
surface, retinal hemorrhage, and macular edema (Figure 1A). 
Fluorescein angiography revealed marked leakage from the 
neovascular vessels (Figure 1B). Spectral-domain optical 
coherence tomographic (OCT) imaging through the fovea 
showed a serous retinal detachment (Figure 1C). An aggres-
sive retinal astrocytoma was suspected, and six monthly 
intravitreal bevacizumab injections (1.25 mg) were performed 
after informed consent following institutional review board 
approval.
After the six monthly intravitreal bevacizumab injec-
tions, the BCVA improved to 0.3. Fundus examination 
demonstrated marked regression of neovascular vessels, 
retinal hemorrhage, and exudative change (Figure 2A). 
Fluorescein angiography revealed decreased leakage from 
neovascular vessels (Figure 2B). OCT imaging through the 
fovea showed disappearance of the serous retinal detach-
ment (Figure 2C). OCT imaging through the elevated lesion 
showed an epiretinal membrane and retinal tumor located on 
the retinal surface (Figure 2D).
Two months later, dense vitreous hemorrhage developed, 
and the BCVA decreased to hand motion. Three days after 
additional intravitreal bevacizumab injection to prevent intra-
operative bleeding, vitrectomy with endophotocoagulation 
was performed. After the epiretinal neovascular membrane 
was peeled off, a soft, gelatinous, light grey mass without 
signs of calcification was found on the retinal surface. The 
surface of the retinal tumor was biopsied after obtaining 
informed consent. Histopathologic analysis of the retinal 
tumor revealed plump spindle-shaped cells with round or 
slightly elongated nuclei (Figure 3). The retinal tumor 
was intensely immunoreactive for vimentin, glial fibrillary 
acidic protein (GFAP), and neuron-specific enolase, being 
consistent with a diagnosis of astrocytoma1 (Figure 4A–C). 
Despite the preceding intravitreal bevacizumab injections, the 
tumor also showed immunoreactivity for VEGF (Figure 4D). 
Immunohistochemical analysis of the surgically removed 
epiretinal membrane demonstrated coexpression of VEGF 
and von Willebrand factor, indicating the presence of VEGF 
in the vascular endothelial cells (Figure 5). A vitreous sample 
was obtained during vitrectomy, and we also measured the 
VEGF concentration in the vitreous fluid by enzyme-linked 
immunosorbent assay (GE Healthcare, Little Chalfont, UK). 
Figure 1 Color fundus photograph, fluorescein angiographic image, and spectral-domain optical coherence tomographic image at the initial visit for a 24-year-old man with 
aggressive retinal astrocytoma. The best-corrected visual acuity was 0.09. (A) Fundus photograph demonstrates an elevated lesion in the superior aspect of the optic disc 
accompanied with marked neovascular vessels located on the surface, retinal hemorrhage, and exudative change. Hard exudates are seen in the macula. (B) Late-phase 
fluorescein angiography reveals marked leakage from the neovascular vessels. (C) Horizontal optical coherence tomographic image through the fovea shows serous retinal 
detachment.
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The vitreous VEGF concentration measured by enzyme-linked 
immunosorbent assay was at undetectable levels. Clinical and 
pathological findings are summarized in Table 1.
Two months after vitrectomy, the BCVA recovered to 0.2. 
Fundus examination revealed photocoagulation scars corre-
sponding to retinal astrocytoma, and OCT imaging showed 
no serous macular detachment (Figure 6). Intraocular pres-
sure remained normal at all times, with no evidence of iris 
neovascularization.
Discussion
Shields et al1 reported four patients with aggressive retinal 
astrocytoma associated with tuberous sclerosis complex. 
All cases had multiple tumors in the fundus. In every case, 
only one larger tumor near the optic disc showed progressive 
growth and retinal detachment, whereas all other tumors 
remained static. An aggressive tumor was also located near 
the disc in our patient. Shields et al1 reported that aggressive 
retinal astrocytoma was composed of two types of cells, ie, 
plump spindle cells and giant cells occasionally with vacu-
olated cytoplasm. All tumors coexpressed neuron-specific 
enolase and GFAP. In general the giant cells were immuno-
reactive for neuron-specific enolase but were negative or only 
minimally reactive for GFAP. In contrast, the spindle cells 
expressed both neuron-specific enolase and GFAP. The tumor 
cells were also strongly immunoreactive for S-100 protein 
and vimentin. In our present case, histopathologic analysis 
of the biopsied retinal tumor revealed plump spindle-shaped 
cells and intense immunoreactivity for vimentin, GFAP, and 
neuron-specific enolase (Table 1).
Figure 2 Color fundus photograph, fluorescein angiographic image, and spectral-domain optical coherence tomographic (OCT) images after six intravitreal injections of 
bevacizumab. The best-corrected visual acuity improved to 0.3. (A) Fundus photograph demonstrates marked regression of neovascular vessels, retinal hemorrhage, and 
exudative change. The direction of the OCT scan is indicated by a white arrow (C) or a black arrow (D). (B) Late-phase fluorescein angiography reveals decreased leakage 
from neovascular vessels. (C) Horizontal OCT image through the fovea shows disappearance of the serous retinal detachment. (D) Vertical OCT image through the elevated 
lesion shows a retinal tumor located on the retinal surface (black arrowhead) and epiretinal membrane (white arrowhead).
Figure 3 Histopathologic analysis of a biopsy sample of the retinal tumor which was 
obtained during pars plana vitrectomy.
Notes:  Plump  spindle-shaped  cells  with  round  or  slightly  elongated  nuclei  are 
observed.  Mitotic  activity  is  not  evident.  Hematoxylin-eosin  staining  was  used. 
Yellow bar represents 100 µm.
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Mennel et al2 published an evidence-based review 
evaluating the incidence of symptomatic retinal astrocytoma. 
According to their analyses, symptomatic changes were 
described in 11 case reports published over a period of three 
decades. The symptomatic alterations were caused by an 
enlarged tumor with leakage, macular edema,   accumulating 
lipoid exudates, serous retinal detachment (eight eyes), and 
vitreous hemorrhage (four eyes). Interventional studies 
showed slow resorption of subretinal fluid after argon laser 
photocoagulation (two eyes), although recurrent laser appli-
cations induced choroidal neovascularization and destruction 
of the neurosensory retina (one eye). Vitrectomy was used 
Figure 4 Immunoreactivity of biopsy sample of retinal tumor for vimentin (A), glial fibrillary acidic protein (B), neuron-specific enolase, (C), and vascular endothelial growth 
factor (D).
Notes: The biopsy sample is intensely immunoreactive for vimentin, glial fibrillary acidic protein, and neuron-specific enolase, being consistent with the diagnosis of 
astrocytoma. The sample also shows moderate immunoreactivity for vascular endothelial growth factor. Yellow bar represents 100 µm.
Figure 5 Immunoreactivity of surgically removed epiretinal membrane for vascular endothelial growth factor (A) and von Willebrand factor (B). (C) Nuclear staining of the 
same section. (D) Triple labeling.
Notes: Despite intravitreal bevacizumab injections, triple labeling demonstrates coexpression of vascular endothelial growth factor and von Willebrand factor, indicating the 
presence of vascular endothelial growth factor in vascular endothelial cells. Yellow bar represents 100 µm.
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to remove a vitreous hemorrhage in one patient. In one case, 
complete resorption of subretinal fluid and an increase in 
visual acuity was observed within 2 weeks after a single 
treatment with photodynamic therapy.
Saito et al3 reported that macular edema secondary to 
aggressive retinal astrocytoma resolved after intravitreal 
bevacizumab injection in two cases. Similarly, macular 
edema regressed remarkably after monthly intravitreal 
bevacizumab injections in our present case. These results 
suggest that VEGF derived from retinal astrocytoma causes 
macular edema and that intravitreal bevacizumab injection is 
effective for resolving the macular edema temporarily. It has 
been shown that hamartomas associated with tuberous scle-
rosis complex involving organs other than the eyes (kidney, 
brain, and skin) are highly angiogenic and may express 
VEGF.3,8,9 As far as we know, there are no reports regard-
ing VEGF expression in the tumor of aggressive retinal 
astrocytoma, although the vitreous VEGF concentration has 
been reported to be high in aggressive retinal astrocytoma 
(Table 1).3 In the present study, we showed VEGF expression 
in both retinal tumor and epiretinal membrane. Therefore, 
VEGF derived from aggressive retinal astrocytoma may 
play a potential role in the pathogenesis of macular edema, 
exudative retinal detachment, and epiretinal neovascular 
membrane secondary to tuberous sclerosis complex. Saito 
et al3 reported that macular edema recurred after intravitreal 
bevacizumab injection in one of two cases and that recurrent 
edema was successfully treated by additional laser photoco-
agulation to the tumors. In the other case, the small tumor 
size might have been one of the causes of no recurrence of 
macular edema after intravitreal bevacizumab injection. In 
our case, vitreous hemorrhage developed after intravitreal 
bevacizumab injection, which necessitated vitrectomy with 
endophotocoagulation. Several intravitreal bevacizumab 
injections led to an undetectable vitreous VEGF concen-
tration. Despite the preceding intravitreal bevacizumab 
injections, the surgically removed epiretinal membrane 
and biopsied retinal tumor expressed VEGF. These results 
suggest that intravitreal bevacizumab injection is effective 
for reducing the vitreous VEGF concentration but insuffi-
cient for completely inhibiting VEGF activity in the tumor. 
Therefore, macular edema or neovascularization may recur 
frequently after intravitreal bevacizumab monotherapy. The 
clinical course and immunohistochemical analyses in our 
Figure  6  Color  fundus  photograph  and  spectral-domain  optical  coherence 
tomographic image after pars plana vitrectomy. The best-corrected visual acuity 
was  0.2.  (A)  Fundus  photograph  demonstrates  retinal  photocoagulation  scars 
corresponding to retinal astrocytoma. Small residual retinal astrocytoma is seen 
in  the  center  of  the  photocoagulation  scars.  (B)  Horizontal  optical  coherence 
tomographic image through the fovea shows no serous retinal detachment.
Table 1 Clinical and pathological findings
Findings
Clinical course
Immediately after six IVBs Marked regression of neovasclar 
vessels and exudative change
Two months after six IVBs Development of vitreous 
hemorrhage
Retinal tumor
Histopathologic analysis Plump spindle-shaped cells with 
round or slightly elongated nuclei
Immunoreactivity for vimentin,  
GFAP, NSE
Intensely positive
Immunoreactivity for VEGF  
(after IVB)
Moderately positive
Immunoreactivity for vimentin,  
GFAP, NSE, S-100  
(4 cases reported by Shields et al1)
Positive (Shields et al1)
Epiretinal membrane
Immunoreactivity for VEGF  
(after IVB)
Moderately positive (coexpression 
with von Willebrand factor)
Vitreous VEGF concentration
After IVB Under detectable levels
Before IVB (one case reported  
by Saito et al3)
68.5 pg/mL (higher than levels in 
control; Saito et al3)
Abbreviations: IVB, intravitreal bevacizumab injection; GFAP, glial fibrillary acidic 
protein; NSE, neuron-specific enolase; VEGF, vascular endothelial growth factor; 
S-100, S-100 protein.
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patient indicate that intravitreal bevacizumab monotherapy 
may have been insufficient to treat aggressive retinal astro-
cytoma with macular edema, and that laser photocoagulation 
or photodynamic therapy for the tumor should be considered 
following intravitreal bevacizumab injection. However, we 
cannot clarify whether combined therapy of intravitreal 
bevacizumab injection and laser photocoagulation or pho-
todynamic therapy is more effective than photodynamic 
therapy alone or not. Accumulation of treated cases with 
aggressive retinal astrocytoma is necessary.
Aggressive retinal astrocytoma shows progressive 
enlargement of the tumor accompanied by total exudative 
retinal detachment and neovascular glaucoma.1 Without 
adequate treatment, enucleation eventually becomes neces-
sary because of blindness and ocular pain.1 Therefore, precise 
diagnosis and prompt treatment are important. In our present 
case, final visual acuity remained at 0.2, presumably because 
of longstanding macular edema at the initial visit. When we 
follow up patients with tuberous sclerosis complex, detect-
ing initial or recurrent macular edema by performing OCT 
in the early stages is mandatory for preventing a poor visual 
prognosis.3
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